Clinical Trial Update: Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors [Phase 1, Phase 2]

View source ↗

Summary

Imatinib Mesylate is being studied in patients with refractory Desmoplastic Small Round Cell Tumor in Phase 1 and Phase 2 cohorts, and the trial status is compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Desmoplastic Small Round Cell Tumor

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Refractory Desmoplastic Small Round Cell Tumors | Phase 1, Phase 2 | Status: COMPLETED